Global office locator

Three months is not enough to start. The final JCA assessment scope can leave developers with roughly three months to submit a dossier. That is not the moment to begin evidence searches, subgroup analyses or indirect com...

How can sponsors maintain patient safety while navigating complex and evolving global regulatory requirements? In The Pharma Letter, Dr. Quintin van Wyk discusses the realities of post-marketing pharmacovigilance, includ...

Advancing a liver disease program starts well before the clinic. Meet ICON’s nonclinical experts at #AASLD26, booth 1861, to discuss integrated development planning, study design, data interpretation and regulatory suppo...

One day to go. Join Shelley Mclendon tomorrow at OCT New England for her presentation "Is AI enough? Why smarter site identification still needs human-centred strategies". Shelley will explore strategies to help biotech ...

Meet us at ESMO, booth \#8005 to discuss how ICON integrates expertise, flexible partnership and delivery models, proven technology and global infrastructure to reduce risk, improve decision making and advance programs f...

Building an AI-enabled SaMD? Don't leave regulatory feedback until the end. Early FDA engagement can help align expectations, strengthen your evidence strategy and keep development on track. Read our latest blog for tip...

Antimicrobial-resistant Neisseria gonorrhoeae represents one of the most pressing challenges in infectious disease, with the WHO targeting a 90% incidence reduction by 2030. Resistance has emerged against nearly every cl...

Meet ICON at #ESMO26, booth \#8005, to discuss how our scientific insight, oncology expertise, connected site network and purpose-built technology can support your program from strategy to study delivery. Explore practic...

Europe’s oncology biosimilar market is entering its next phase. Scientific methods are advancing, regulatory expectations are evolving and more biologics are approaching loss of protection. Yet securing regulatory appro...

Heading to #ObesityWeek? Connect with ICON experts at booth \#212 to explore how our cross-functional obesity expertise and integrated scientific and operational support can help navigate the complexities of obesity deve...

Healthcare decisions depend on evidence that is relevant, rigorous and meaningful. At #ISPOREurope2026, ICON and Mapi Research Trust will be sharing research across multiple poster sessions, covering clinical outcome ass...

Biopsies remain the gold standard in MASH clinical trials, but they are far less common in everyday clinical practice. As more patients are diagnosed and managed using non-invasive tests, the gap between routine care a...